Sainte Catherine, Institut du Cancer Avignon-Provence (ICAP), Becomes the First Center in Europe to Implement the Varian Latest Halcyon Advancements with Identify integration, PerfectKinetix Dynamic Couch and HyperSight for Personalized Radiotherapy
Institut du Cancer Avignon-Provence (ICAP), and Varian, a Siemens Healthineers company, announced today the first European installation of the Halcyon version 5.0 radiotherapy platform, combined with IDENTIFY real-time motion management, and the PerfectKinetix Dynamic Couch. This milestone marks a significant step forward in delivering more precise, efficient, and personalized radiotherapy, while enhancing the overall patient experience.
The latest evolution of Varian’s Halcyon platform brings together enhanced patient positioning, real-time motion management with IDENTIFY, and embedded high-quality HyperSight imaging. ICAP’s adoption of this ecosystem reflects its commitment to offering patients in the region access to the latest innovations in radiation oncology.
Advancing Personalized Care
The combination of Halcyon 5.0 and IDENTIFY 5.0 enables clinicians to deliver treatment more effectively by supporting individualized care plans.
- IDENTIFY* integration is designed to improve positioning options, provide automated beam control, and simplify workflows.
- Embedded HyperSight* shortens imaging sessions with scans that are better, faster, bigger, and have shown to make a difference in patient treatments.
- The new PerfectKinetix Dynamic Couch* accelerates patient positioning and aims to improve comfort.
Together these innovations aim to streamline complex workflows and help clinicians personalize treatment with greater confidence.
Enhancing the Patient Experience
Halcyon was built to maximize efficiency and treat more effectively. With these latest advancements, Halcyon elevates the patient experience through shorter imaging sessions, streamlined positioning workflows, and smooth single motion couch adjustment. For patients, these improvements are intended to reduce immobilization time, enhance comfort and minimize stress during treatment.
The system is now fully operational at ICAP, which has already begun treating its first patients using the Halcyon 5.0 setup.
“The combined functionalities of Halcyon 5.0 and Identify 5.0 enable clinicians to deliver high-precision treatments with greater confidence and safety, while enhancing the patient experience through improved efficiency,” said Dr Catherine Khamphan, Medical physicist and Head of Research and Development at ICAP. “It is impressive to see how Varian has succeeded in responding to the needs of therapists, physicists, and oncologists with this new radiotherapy platform.”
For Dr Pierre Trémolières, Radiation Oncologist and GI specialist at ICAP, “These innovations could open the door to new treatment possibilities in our center, such as dose escalation in adaptive radiotherapy for pancreatic cancer while preserving surrounding organs at risk. Treatment options for pancreatic cancer remain limited, and offering new therapeutic strategies is crucial.”
“We are proud to see Institut du Cancer Avignon-Provence, lead the way as the first center in Europe to adopt the Halcyon 5.0 ecosystem,” said Virve Sarja, Head of Varian for Europe, Middle East and Africa. “This installation reflects our commitment to supporting cancer centers and clinical teams with innovative solutions that elevate precision, improve the patient experience, and make personalized care more accessible. Together, we are shaping a future where radiotherapy is more accessible, more patient-centered, and aligned with the highest standards of care.”
© 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners.
- *Automated beam hold requires the optional Connect IDENTIFY feature.
- *An optional feature on Halcyon.
"Halcyon 5.0 and Identify 5.0 are not available for sale in all markets."
QR700032647
About Sainte-Catherine - Institut du Cancer - Avignon-Provence
Founded in 1946, Sainte-Catherine is a medical institution specializing in cancer screening and treatment. As a private, non-profit healthcare organization recognized as being of public interest, Sainte-Catherine fulfills public service missions in oncology including care, prevention, research, and education.
With the expertise of its clinical teams, advanced technical capabilities, and active clinical research programs, Sainte-Catherine ranks among the leading cancer centers in France.
The institution has been ISO 9001 certified since 2018 for its clinical trial investigations.
Sainte-Catherine has been an affiliated member of Unicancer since 202.
Key Figures | ||
• 19 500 patients treated per year annually | • 2 700 new patients | |
• 48 000 radiotherapy sessions per year | • 20 500 chemotherapy sessions per year | |
• 36 000 medical consultations annually | • 101 inpatient beds and 59 outpatient places | |
About Varian, a Siemens Healthineers company
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251210623911/en/
Contacts
Press Contact
Kristin Corey
Varian Corporate Communications
Kristin.Corey@varian.com
Karine CHESNEL
Responsable communication & mécénat Sainte-Catherine, Institut du Cancer Avignon
- Provence
Tél. : +33 (0)4 90 27 60 50
k.chesnel@isc84.org
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Announces Five Data Center Predictions Report for 202613.1.2026 12:04:00 CET | Press Release
Uptime Institute today announced the release of its Five Data Center Predictions for 2026 looking beyond the more obvious trends of 2026 and examining some of the latest developments and challenges shaping the digital infrastructure industry. The 2026 predictions focus on the continued growth of the industry and related challenges, while also recognizing AI as a powerful, transformative accelerant to growth. While AI is the key driver for a wave of investment that will underpin digital infrastructure for decades to come, the speed and ultimate size of the build-outs are unclear at this time. “Critical digital infrastructure continues to expand strongly,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “At the same time, our research shows uncertainty about how AI will reshape demand. This is complicating both capacity planning and resiliency strategies. We are also seeing increasing fragmentation in the design and deployment of data centers and expect investment a
BeOne Medicines Highlights Global Oncology Leadership at 44 th Annual J.P. Morgan Healthcare Conference13.1.2026 12:00:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). In addition, Mr. Oyler will share further information on BeOne’s global development superhighway, which encompasses global, wholly internal, and competitively advantaged
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research13.1.2026 12:00:00 CET | Press Release
BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework. The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures. As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatrix replaces unstructured, ungoverned usage with compliant distribution that preserves attribution and entitlements. For research firms, the partnership p
Vaudoise Becomes First Swiss Insurer to Go-Live with Guidewire Cloud Platform13.1.2026 11:21:00 CET | Press Release
Vaudoise and Guidewire (NYSE: GWRE) have announced that Vaudoise has become the first Swiss insurer to go-live on Guidewire Cloud Platform. The company has successfully implemented Guidewire ClaimCenter and is currently integrating Guidewire PolicyCenter. By adopting Guidewire Cloud Platform, Vaudoise joins a global community of insurers focusing on insurance excellence with core modernization from a scalable, secure and rapidly updatable cloud delivery model. Arno Suess, Head of P&C Claims at Vaudoise, said: “We are very proud of this milestone, which sets a new benchmark for our industry. With Guidewire Cloud Platform, we can now process motor insurance claims faster, with greater automation and fully digital processes. The result: faster decisions, more transparency, and a seamless experience for customers during critical moments in their lives.” Mathias Grobet, EMEA VP at Guidewire, said: “Vaudoise is well-known for its customer focus, operational excellence and agility – qualities
Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth13.1.2026 11:15:00 CET | Press Release
Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/ Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets Ant International is focused on improving access to payments, credit, digital banking and cross-border connectivity in fast-growing but fragmented digital economies. The company currently serves more than 150 million merchants globally, 90% of which are SMEs. “In the world’s fastest growing emerging markets, real-world, trusted and scalable adoption of AI and other new technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom